Samil PharmaceuticalLtd (A000520) Stock Overview
Engages in the manufacture and sale of pharmaceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A000520 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Samil Pharmaceutical Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,100.00 |
| 52 Week High | ₩12,860.00 |
| 52 Week Low | ₩5,500.00 |
| Beta | 0.34 |
| 1 Month Change | 10.42% |
| 3 Month Change | -20.40% |
| 1 Year Change | -29.07% |
| 3 Year Change | -7.55% |
| 5 Year Change | -21.74% |
| Change since IPO | 492.32% |
Recent News & Updates
Samil Pharmaceutical Co.,Ltd's (KRX:000520) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Samil Pharmaceutical Co.,Ltd's ( KRX:000520 ) price-to-sales (or "P/S") ratio of 1x...We Think Samil PharmaceuticalLtd (KRX:000520) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Recent updates
Shareholder Returns
| A000520 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 21.8% | 13.1% | 16.9% |
| 1Y | -29.1% | -11.3% | 95.2% |
Return vs Industry: A000520 underperformed the KR Pharmaceuticals industry which returned -11.3% over the past year.
Return vs Market: A000520 underperformed the KR Market which returned 95.2% over the past year.
Price Volatility
| A000520 volatility | |
|---|---|
| A000520 Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in KR Market | 17.8% |
| 10% least volatile stocks in KR Market | 5.1% |
Stable Share Price: A000520 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A000520's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 583 | Seung Bum Huh | www.samil-pharm.com |
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophthalmic drops; and Herpecid, Forus, and Ocurasin ophthalmic ointments.
Samil Pharmaceutical Co.,Ltd Fundamentals Summary
| A000520 fundamental statistics | |
|---|---|
| Market cap | ₩149.81b |
| Earnings (TTM) | -₩36.42b |
| Revenue (TTM) | ₩210.51b |
Is A000520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000520 income statement (TTM) | |
|---|---|
| Revenue | ₩210.51b |
| Cost of Revenue | ₩134.77b |
| Gross Profit | ₩75.75b |
| Other Expenses | ₩112.16b |
| Earnings | -₩36.42b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70k |
| Gross Margin | 35.98% |
| Net Profit Margin | -17.30% |
| Debt/Equity Ratio | 127.5% |
How did A000520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/06 10:19 |
| End of Day Share Price | 2026/08/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Samil Pharmaceutical Co.,Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiwon Lee | Heungkuk Securities Co., Ltd |